Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Penumbra, Inc. stock logo
PEN
Penumbra
$289.52
-2.2%
$278.62
$148.00
$310.00
$11.21B0.53433,363 shs1.48 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$73.46
-1.3%
$65.05
$36.93
$80.99
$3.70B-2.67742,421 shs825,476 shs
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$28.01
-0.9%
$27.46
$23.69
$31.72
$12.27B0.68808,066 shs394,145 shs
Solventum Co. stock logo
SOLV
Solventum
$70.95
-3.5%
$69.93
$47.16
$85.92
$12.27BN/A1.26 million shs1.40 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Penumbra, Inc. stock logo
PEN
Penumbra
-2.09%+0.30%+6.92%+6.07%+38.71%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-1.32%-1.61%+4.94%+43.11%+68.87%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
-0.85%-1.22%+7.61%+8.88%+8.71%
Solventum Co. stock logo
SOLV
Solventum
-3.77%+8.20%+4.51%-4.49%+9.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Penumbra, Inc. stock logo
PEN
Penumbra
4.3338 of 5 stars
2.44.00.03.73.32.51.9
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.5945 of 5 stars
4.61.00.04.62.73.30.6
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.1607 of 5 stars
1.03.02.50.02.90.03.1
Solventum Co. stock logo
SOLV
Solventum
1.398 of 5 stars
3.03.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.404.45% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.11
Buy$106.7845.35% Upside
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.00
Hold$28.00-0.04% Downside
Solventum Co. stock logo
SOLV
Solventum
2.00
Hold$79.0011.35% Upside

Current Analyst Ratings Breakdown

Latest SLNO, SOLV, SNN, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$80.00 ➝ $78.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/1/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$27.00 ➝ $28.00
4/30/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$84.00 ➝ $80.00
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$301.00 ➝ $318.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$315.00 ➝ $330.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Penumbra, Inc. stock logo
PEN
Penumbra
$1.24B9.04$2.76 per share105.01$29.88 per share9.69
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.81B2.11$3.50 per share8.00$11.94 per share2.35
Solventum Co. stock logo
SOLV
Solventum
$8.31B1.48N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$1.06851.5357.792.831.17%9.74%7.35%7/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263M$2.1612.9714.011.26N/AN/AN/AN/A
Solventum Co. stock logo
SOLV
Solventum
N/A$2.1632.8512.921.94N/AN/AN/AN/A

Latest SLNO, SOLV, SNN, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Solventum Co. stock logo
SOLV
Solventum
$1.19$1.34+$0.15$0.78$2.02 billion$2.07 billion
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
3/5/2025Q4 2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.86-$1.27-$0.41-$1.27N/AN/A
2/18/2025Q4 2024
Penumbra, Inc. stock logo
PEN
Penumbra
$0.88$0.97+$0.09$0.86$311.63 million$315.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.893.18%N/A41.20%N/A
Solventum Co. stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A

Latest SLNO, SOLV, SNN, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.44702.5%3/28/20253/28/20255/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.63
2.51
1.11
Solventum Co. stock logo
SOLV
Solventum
2.45
1.15
0.83

Institutional Ownership

CompanyInstitutional Ownership
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%
Solventum Co. stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
12.30%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%
Solventum Co. stock logo
SOLV
Solventum
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
3,90038.73 million36.59 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million37.81 millionOptionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
20,100437.96 million432.83 millionOptionable
Solventum Co. stock logo
SOLV
Solventum
22,000173.00 millionN/AOptionable

Recent News About These Companies

Solventum: Q1 Earnings Snapshot
Solventum Reports First Quarter 2025 Financial Results
Q1 2025 Solventum Corp Earnings Call
Solventum Corporation: Cheap, With Caveats

New MarketBeat Followers Over Time

Media Sentiment Over Time

Penumbra stock logo

Penumbra NYSE:PEN

$289.52 -6.53 (-2.21%)
As of 05/14/2025 03:47 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$73.46 -0.98 (-1.32%)
As of 05/14/2025 04:00 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Smith & Nephew stock logo

Smith & Nephew NYSE:SNN

$28.01 -0.26 (-0.92%)
As of 05/14/2025 03:48 PM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$70.95 -2.57 (-3.50%)
As of 05/14/2025 03:48 PM Eastern

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.